ValuEngine downgraded shares of Female Health Company (The) (NASDAQ:VERU) from a hold rating to a sell rating in a report published on Tuesday morning.
Several other brokerages have also recently weighed in on VERU. Zacks Investment Research upgraded Female Health Company (The) from a hold rating to a buy rating and set a $2.50 price target for the company in a research report on Wednesday, September 27th. HC Wainwright reiterated a buy rating and set a $5.00 price target on shares of Female Health Company (The) in a research report on Wednesday, October 4th. Finally, Rodman & Renshaw began coverage on Female Health Company (The) in a research report on Wednesday, July 26th. They set a buy rating and a $5.00 price target for the company.
Shares of Female Health Company (NASDAQ:VERU) remained flat at $$1.29 during trading hours on Tuesday. The company had a trading volume of 36,020 shares, compared to its average volume of 110,356.
Female Health Company (The) (NASDAQ:VERU) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.05. The company had revenue of $4.31 million during the quarter, compared to analysts’ expectations of $2.20 million. Female Health Company (The) had a negative return on equity of 16.78% and a negative net margin of 42.02%. research analysts expect that Female Health Company will post -0.17 EPS for the current fiscal year.
In related news, Director Harry Fisch purchased 34,250 shares of Female Health Company (The) stock in a transaction that occurred on Wednesday, September 13th. The stock was bought at an average cost of $1.51 per share, for a total transaction of $51,717.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mitchell Shuster Steiner purchased 100,000 shares of Female Health Company (The) stock in a transaction that occurred on Friday, September 15th. The shares were bought at an average price of $1.63 per share, with a total value of $163,000.00. Following the completion of the transaction, the insider now owns 7,764,767 shares of the company’s stock, valued at approximately $12,656,570.21. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 146,975 shares of company stock valued at $234,279. 10.90% of the stock is owned by company insiders.
About Female Health Company (The)
Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Female Health Company (The)? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Female Health Company (The) and related companies.